Dr. Angelos M. Stergiou, MD, is Founder, Vice Chairman and Chief Executive Officer of SELLAS Life Sciences Group, a biopharmaceutical company that is pioneering the cancer vaccination field. The one that’s receiving the most attention is the WT1 cancer vaccine, galinpepimut-S.
In the Phase 2 clinical trial of the WT1 cancer vaccine, Dr. Angelos M. Stergiou, MD, ScD h.c. and the team at SELLAS Life Sciences Group celebrated promising results. If findings continue to follow the current pattern, the WT1 cancer vaccine could begin saving lives in the near future.
- The WT1 Vaccine. The National Cancer Institute has identified the WT1 antigen as the #1 target for immunotherapeutic treatment. This antigen is rarely found in healthy adult cells, but it is routinely found in cancerous tumors and even some cancer stem cells. By teaching the body to target the WT1 antigen, SELLAS Life Sciences Group’s vaccine effectively allows patients’ T cells to kill cancer from within.
The WT1 cancer vaccine could help fight as many as twenty types of cancer.
- Study Results. In the Phase 2 clinical trial, the WT1 cancer vaccine improved patient survival rate and lengthened periods of remission when compared to the control group. Though the vaccine is not yet ready for public use, as of 2016, upcoming trials and research offer exciting possibilities.
As CEO of SELLAS Life Sciences Group, Dr. Angelos M. Stergiou, MD, ScD h.c. Has given numerous presentations speaking about SELLAS Life Sciences Group’s WT1 cancer vaccine and, in a 2016 interview, he described the possibility of it helping patients in the near future as “breathtaking.”